Germany· DE-A57-16bf7b9d1e70cc98
Thiotepa Hikma
A thiotepa product containing thiotepa, registered in Germany by Hikma Farmacêutica (Portugal), S.A.. The same ATC class is registered in 16 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Thiotepa is registered in 16 of 19 countries.
Countries holding a registration under ATC L01AC01 (thiotepa), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 9 of them publish a price we can compare per daily dose
Thiotepa · ATC L01AC01
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Thiotepa
- Manufacturer
- Hikma Farmacêutica (Portugal), S.A.
- Country
- Germany (DE)
- ATC code
- L01AC01
- ATC class
- Thiotepa
- Defined daily dose
- 1.62 g, P
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
202 interactions on record for thiotepa.
Graded by severity as the source publishes them — 43 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Thiotepa · interactions on record
202 records
- 43 severe
- 105 moderate
- 14 minor
- 40 info
Most severe, free to view
- Nalidixic acidJ01MB02severe
- CyclophosphamideL01AA01severe
- ChlorambucilL01AA02severe
- MelphalanL01AA03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01AC01
Thiotepa, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d98f6070-2b0c-4168-a3af-2152aa7abfd4 GET /v1/drugs/d98f6070-2b0c-4168-a3af-2152aa7abfd4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Intravenous Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Thiotepa",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about thiotepa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.